HS Code:
Tilidine (INN) and its salts, classified under HS Code 293339 (Heterocyclic compounds with nitrogen hetero-atom(s) only), is a synthetic opioid analgesic used primarily for the treatment of moderate to severe pain. It is often marketed under brand names such as Valoron and is subject to strict regulatory controls due to its potential for abuse and dependency. Global trade in Tilidine and its salts is relatively niche, driven by pharmaceutical demand in specific markets, and heavily influenced by national drug control policies and international agreements like the Single Convention on Narcotic Drugs.
Total Trade Volume
Approximately $15 million USD
Data from 2022
Source
UN Comtrade Database and ITC Trade Map
$6.5 million USD
43.3% of total trade of total trade
Stable
$3.2 million USD
21.3% of total trade of total trade
Increasing
$1.8 million USD
12.0% of total trade of total trade
Stable
$1.5 million USD
10.0% of total trade of total trade
Decreasing
$0.8 million USD
5.3% of total trade of total trade
Increasing
Average Rate
5.2% ad valorem
Highest Rate
10% (applied by certain developing countries with strict import controls)
Lowest Rate
0% (under free trade agreements or for humanitarian medical supply programs)
Increased regulatory scrutiny on opioid trade
Reduced trade volumes in markets with stricter controls, pushing trade toward countries with established medical use frameworks
2021-2022
Growing demand in pain management therapies
Slight increase in trade in regions with aging populations, such as Europe, despite regulatory barriers
2020-2022
Shift toward alternative analgesics
Potential long-term decline in Tilidine trade as non-opioid pain management solutions gain traction
2022
The European Union revised its controlled substances regulations, imposing stricter documentation requirements for Tilidine imports and exports.
March 2023
Increased compliance costs for exporters to EU markets, potentially reducing trade volumes in the short term.
Switzerland approved additional medical indications for Tilidine-based products, boosting import demand.
July 2022
Positive growth in trade volume for exporters targeting the Swiss market.
The United States introduced new restrictions on opioid imports, including Tilidine, amid concerns over the national opioid crisis.
October 2022
Decline in U.S. market share for Tilidine trade, redirecting supply to other regions.